Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
British Journal of Haematology|June 7, 2018
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trialsJeffrey Jones, Anthony Mato, Steven Coutre, et al.
Blood|February 14, 2018
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experienceSusan O'Brien, Richard R Furman, Steven Coutre, et al.
British Journal of Haematology|April 12, 2017
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinibJeffrey A Jones, Peter Hillmen, Steven Coutre, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2021
Plasma Microbial Cell-free DNA Next-generation Sequencing in the Diagnosis and Management of Febrile NeutropeniaEsther Benamu, Kiran Gajurel, Jill N Anderson, et al.
American Journal of Hematology|February 16, 2019
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysisSusan M O'Brien, John C Byrd, Peter Hillmen, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 1, 2018
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell LymphomaSusan O'Brien, Peter Hillmen, Steven Coutre, et al.
Blood|January 20, 2018
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AMLRonan T Swords, Steven Coutre, Michael B Maris, et al.
The Lancet. Oncology|December 17, 2017
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trialJeffrey A Jones, Anthony R Mato, William G Wierda, et al.
Haematologica|June 9, 2018
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2Paul M Barr, Tadeusz Robak, Carolyn Owen, et al.
American Journal of Hematology|September 13, 2019
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphomaTalha Munir, Jennifer R Brown, Susan O'Brien, et al.
Pageof 5